86 related articles for article (PubMed ID: 8007673)
1. Local hyperthermia abrogates the anti-immunotherapeutic effect of interleukin-8.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1994 Jun; 56(2):102-6. PubMed ID: 8007673
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte migration to tumors after hyperthermia and immunotherapy.
Midis GP; Fabian DF; Lefor AT
J Surg Res; 1992 May; 52(5):530-6. PubMed ID: 1619922
[TBL] [Abstract][Full Text] [Related]
3. Combined local hyperthermia and immunotherapy treatment of an experimental subcutaneous murine melanoma.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1995 May; 59(1):35-9. PubMed ID: 7745975
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor alpha mediates the antitumor effect of combined interleukin-2 and whole body hyperthermia.
Fritz KL; Koziol S; Fabian DF; Lefor AT
J Surg Res; 1996 Jan; 60(1):55-60. PubMed ID: 8592432
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 and syngeneic bone marrow transplantation in a murine fibrosarcoma model.
Ho SP; Stebler B; Ershler WB
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):101-4. PubMed ID: 1873353
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-8 suppresses the toxicity and antitumor effect of interleukin-2.
Heniford BT; Edwards MJ; Wilson MA; Klar EA; Doak KW; Miller FN
J Surg Res; 1994 Jan; 56(1):82-8. PubMed ID: 8277774
[TBL] [Abstract][Full Text] [Related]
7. Transfection of a murine fibrosarcoma with intercellular adhesion molecule-1 enhances the response to adoptive immunotherapy.
Burno DK; Kyprianou N; Sartor WM; Fabian DF; Turner J; Vu T; Patel A; Trimbach C; Lefor AT
Surgery; 1995 Aug; 118(2):237-43; discussion 243-4. PubMed ID: 7638739
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet.
Fujiwara T; Sakagami K; Matsuoka J; Shiozaki S; Fujioka K; Takada Y; Uchida S; Onoda T; Orita K
Biotherapy; 1991; 3(3):203-9. PubMed ID: 1854589
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
[TBL] [Abstract][Full Text] [Related]
10. Effect of host age upon interleukin-2-mediated anti-tumor responses in a murine fibrosarcoma model.
Ho SP; Kramer KE; Ershler WB
Cancer Immunol Immunother; 1990; 31(3):146-50. PubMed ID: 2337904
[TBL] [Abstract][Full Text] [Related]
11. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
Wakizaka Y
Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy and whole-body hyperthermia as combined modality treatment of a subcutaneous murine sarcoma.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1993 Jul; 53(3):180-3. PubMed ID: 8331940
[TBL] [Abstract][Full Text] [Related]
13. Combined hyperthermia and immunotherapy treatment of multiple pulmonary metastases in mice.
Strauch ED; Fabian DF; Turner J; Lefor AT
Surg Oncol; 1994 Feb; 3(1):45-52. PubMed ID: 8186870
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
[TBL] [Abstract][Full Text] [Related]
15. NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice.
Orucevic A; Lala PK
Br J Cancer; 1996 Jan; 73(2):189-96. PubMed ID: 8546905
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model.
Mao XW; Kettering JD; Gridley DS
Cancer Biother; 1994; 9(4):317-27. PubMed ID: 7719379
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells.
Wu B; Shen RN; Wang WX; Broxmeyer HE; Lu L
Stem Cells; 1993 Sep; 11(5):412-21. PubMed ID: 8241952
[TBL] [Abstract][Full Text] [Related]
18. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy with low-dose interleukin-2 and a polysaccharopeptide derived from Coriolus versicolor.
Mao XW; Archambeau JO; Gridley DS
Cancer Biother Radiopharm; 1996 Dec; 11(6):393-403. PubMed ID: 10851500
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of interleukin 2-induced pulmonary vascular leak syndrome by low doses of oral methotrexate.
DeJoy SQ; Jeyaseelan R; Torley LW; Schow SR; Wick MM; Kerwar SS
Cancer Res; 1995 Nov; 55(21):4929-35. PubMed ID: 7585532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]